Can Tricky Elderly AML Population Justify Weak Data? Fate Of Genzyme's Clolar and Vion's Onrigin Rests With ODAC
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's briefing documents for the Sept. 1 review suggest the single-arm Phase II trials are not sufficient; the wild card will be whether the panel thinks better trials can be done in that population.
You may also be interested in...
Genzyme Recovery Is Taking Off, Termeer Says
Ahead of an important investor meeting in New York on Friday, Genzyme reported third quarter sales showing signs that drug supply constraints are improving.
Genzyme Recovery Is Taking Off, Termeer Says
Ahead of an important investor meeting in New York on Friday, Genzyme reported third quarter sales showing signs that drug supply constraints are improving.
No Regulatory Slack For Tough Supplemental Indications, Pazdur Tells ODAC
FDA may hold approval of supplemental indications to a higher standard of evidence than what can feasibly be obtained since the drugs are already available to treat patients in an off-label setting, FDA Office of Drug Oncology Products Director Richard Pazdur indicated at a Sept. 1 advisory committee meeting